AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M

AVITA Medical, Inc.

CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
Board member Jan Reed appointed Lead Independent Director; search for permanent CEO commenced.
Preliminary Q3 2025 revenue expected ~$17M; company to provide update on Nov 6 earnings call.
OrbiMed waived Q3 2025 trailing 12-month net revenue covenant; discussions underway to redefine future covenants.
Departure not due to any disagreement with the company on operations, policies, or practices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.